Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    February 2022
  1. JIANG Y, Southam AD, Trova S, Beke F, et al
    Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing.
    Br J Cancer. 2022;126:275-286.
    PubMed     Abstract available


  2. SUBHASH VV, Huang L, Kamili A, Wong M, et al
    Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.
    Br J Cancer. 2022;126:482-491.
    PubMed     Abstract available


    September 2021
  3. TARIQ MU, Furqan M, Parveen H, Ullah R, et al
    CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
    Br J Cancer. 2021;125:966-974.
    PubMed     Abstract available


    July 2021
  4. MOGENSEN H, Modig K, Talback M, Erdmann F, et al
    Number of siblings and survival from childhood leukaemia: a national register-based cohort study from Sweden.
    Br J Cancer. 2021;125:112-118.
    PubMed     Abstract available


  5. KARSA M, Kosciolek A, Bongers A, Mariana A, et al
    Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
    Br J Cancer. 2021;125:55-64.
    PubMed     Abstract available


    May 2021
  6. SONG S, Zhang J, Su Q, Zhang W, et al
    Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.
    Br J Cancer. 2021;124:1843-1853.
    PubMed     Abstract available


    February 2021
  7. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    PubMed     Abstract available


    January 2021
  8. BARROW TM, Nakjang S, Lafta F, Bilotkach K, et al
    Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
    Br J Cancer. 2021;124:474-483.
    PubMed     Abstract available


    December 2020
  9. PUETT RC, Poulsen AH, Taj T, Ketzel M, et al
    Relationship of leukaemias with long-term ambient air pollution exposures in the adult Danish population.
    Br J Cancer. 2020;123:1818-1824.
    PubMed     Abstract available


    October 2020
  10. GUILLEMETTE C, Rouleau M, Vanura K, Levesque E, et al
    Reply to Comment on "UGT2B17 modifies drug response in chronic lymphocytic leukaemia".
    Br J Cancer. 2020;123:1347-1348.
    PubMed    


  11. PAPAMICHOS SI, Jungbauer C
    Comment on: "UGT2B17 modifies drug response in chronic lymphocytic leukaemia".
    Br J Cancer. 2020;123:1345-1346.
    PubMed    


    September 2020
  12. SHIN AR, Lee SE, Choi H, Sohn HJ, et al
    An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
    Br J Cancer. 2020;123:919-931.
    PubMed     Abstract available


  13. ALRUWETEI AM, Bendak K, Yadav BD, Carol H, et al
    Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
    Br J Cancer. 2020;123:742-751.
    PubMed     Abstract available


    July 2020
  14. ALLAIN EP, Rouleau M, Vanura K, Tremblay S, et al
    UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
    Br J Cancer. 2020;123:240-251.
    PubMed     Abstract available


    June 2020
  15. TOSCAN CE, Jing D, Mayoh C, Lock RB, et al
    Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
    Br J Cancer. 2020;122:1769-1781.
    PubMed     Abstract available


    May 2020
  16. LIU J, Hong J, Han H, Park J, et al
    Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration.
    Br J Cancer. 2020;122:1445-1452.
    PubMed     Abstract available


    April 2020
  17. YANG J, Meng C, Weisberg E, Case A, et al
    Inhibition of the deubiquitinase USP10 induces degradation of SYK.
    Br J Cancer. 2020;122:1175-1184.
    PubMed     Abstract available


  18. CREMER A, Stegmaier K
    Targeting DUBs to degrade oncogenic proteins.
    Br J Cancer. 2020;122:1121-1123.
    PubMed     Abstract available


    February 2020
  19. TAVAKOLI SHIRAZI P, Eadie LN, Heatley SL, Hughes TP, et al
    The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.
    Br J Cancer. 2020;122:455-464.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: